Calnexin and other factors that alter translocation affect the rapid binding of ubiquitin to apoB in the Sec61 complex.
Several secretory proteins, including apolipoprotein B, have been shown to undergo degradation by proteasomes. We found that the rapid degradation of nascent apolipoprotein B in HepG2 cells was diminished but not abolished by the addition of any of three different inhibitors of proteasomes. Ubiquitin is conjugated to apolipoprotein B that is not assembled with sufficient lipids either during or soon after synthesis. In addition, we found that apolipoprotein B that has entered the endoplasmic reticulum sufficiently to become glycosylated can be degraded by proteasomes. Furthermore, we detected ubiquitin-apolipoprotein B that is associated with the Sec61 complex, the major constituent of the translocational channel. Treatment of cells with monomethylethanolamine or dithiothreitol decreased the translocation of apolipoprotein B and increased the proportion of ubiquitin-conjugated molecules associated with Sec61. Conversely, treatment of cells with oleic acid, which increased the proportion of translocated apolipoprotein B, decreased the amount of ubiquitin-apolipoprotein B in the Sec61 complex. Finally, we found that inhibition of the interaction between calnexin and apolipoprotein B decreases the translocation of apolipoprotein B, increases the ubiquitin-apolipoprotein B in the Sec61 complex, and increases the proteasomal degradation of glycosylated apolipoprotein B. Thus, ubiquitin can be attached to unassembled apolipoprotein B in the Sec61 complex, and this process is affected by factors including calnexin that alter the translocation of apolipoprotein B.
Chen
Y
Y
Molecular Medicine Unit, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
Le Cahérec
F
F
Chuck
S L
SL
D001055:Apolipoproteins B / Q000378:metabolism* / Q000648:ultrastructure; D001692:Biological Transport; D002135:Calcium-Binding Proteins / Q000378:metabolism*; D037281:Calnexin; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D004229:Dithiothreitol / Q000494:pharmacology; D004721:Endoplasmic Reticulum / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D007212:Indolizines / Q000494:pharmacology; D046911:Macromolecular Substances; D008565:Membrane Proteins / Q000378:metabolism*; D009097:Multienzyme Complexes / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex; D011485:Protein Binding; D017510:Protein Folding; D000069816:SEC Translocation Channels; D014407:Tumor Cells, Cultured; D014452:Ubiquitins / Q000378:metabolism*; D054836:Indolizidines
D001055:Apolipoproteins B; D002135:Calcium-Binding Proteins; D037281:Calnexin; D003546:Cysteine Endopeptidases; D004229:Dithiothreitol; D007212:Indolizines; D046911:Macromolecular Substances; D008565:Membrane Proteins; D009097:Multienzyme Complexes; D046988:Proteasome Endopeptidase Complex; D000069816:SEC Translocation Channels; D014452:Ubiquitins; C037806:castanospermine; D054836:Indolizidines